Hologic (NASDAQ:HOLX) Hits New 12-Month Low – Should You Sell?

Shares of Hologic, Inc. (NASDAQ:HOLX) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $61.42 and last traded at $61.55, with a volume of 144189 shares. The stock had previously closed at $62.59.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research note on Monday, February 3rd. Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Stephens reaffirmed an “overweight” rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Down 0.7 %

The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market capitalization of $13.62 billion, a P/E ratio of 19.15, a PEG ratio of 2.14 and a beta of 0.97. The company has a 50 day moving average of $67.65 and a 200-day moving average of $74.94.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. FMR LLC grew its stake in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the period. Norges Bank bought a new stake in shares of Hologic during the 4th quarter valued at $133,414,000. Boston Partners grew its position in shares of Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after buying an additional 1,602,463 shares during the period. Champlain Investment Partners LLC bought a new position in shares of Hologic in the 4th quarter worth about $79,291,000. Finally, Northern Trust Corp lifted its position in Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider’s stock valued at $226,898,000 after acquiring an additional 668,086 shares during the period. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.